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Introduction
DMD#9878
in a later development stage to help provide a mechanistic insight for the interpretation of interactions observed clinically (Prueksaritanont et al., 2002) . For metabolic interaction studies, this approach requires that the animal model possesses similarities to humans with respect to enzymatic activities, in the absence and presence of an enzyme inducer or inhibitor of interest, as well as the basic in vivo ADME characteristics of a selected probe substrate. In this regard, rhesus monkeys (Macaca mulatta) and cynomologous monkeys (Macaca fascicularis), non-human primates widely used in the pharmaceutical industry for preclinical evaluations of drug absorption and disposition as well as safety and toxicity, have generally been considered to be more appropriate animal models than rodents for drug metabolism studies, based on the sequence and functional activity similarities of drug metabolizing enzymes (Sharer et al., 1995; Igarashi et al., 1997; Kanazu et al., 2004) . Recently, rhesus monkey CYP3A64 has been cloned and characterized in vitro, in comparison with human CYP3A4 and members of CYP3A from other preclinical species (Carr et al., manuscript in review) . The results showed that CYP3A64 was most similar, in protein sequences and functional activities, to human CYP3A4, suggesting that the rhesus monkey may serve as a valuable preclinical model to assess CYP3A-mediated drug interactions. However, the susceptibility of CYP3A64 to known enzyme inhibitors and inducers, both in vitro and in vivo, has not been studied.
Thus, to help assess the potential utility of the rhesus monkey as a preclinical model for studying CYP3A-mediated drug interactions, we set out to evaluate 1) the in vitro induction and inhibition susceptibility profiles of rhesus monkey CYP3A64, relative to human CYP3A4, 2) the corresponding in vivo pharmacokinetic consequences, and 3) the respective in vitro -in vivo induction and inhibition relationships in rhesus monkeys. Rifampin, a potent inducer of CYP3A4 (Neimi et al., 2003) and compound A (structure shown in Chiba et al., 1995) , previously shown to be a potent and selective CYP3A4 inhibitor (Chiba et al., 1995; Lin et al., 1995) , were chosen as a model inducer and inhibitor, respectively. Midazolam (MDZ), a well established and highly DMD#9878 containing the CYP3A4, CYP3A5, and CYP3A7 genes. The CYP3A64 set was validated against plasmid DNA containing the CYP3A64 gene. Quantitation of the target cDNA in treated samples versus DMSO (vehicle) control samples was calculated by correcting for the 18 rRNA in each sample (∆Ct) using the equation: Fold Change = 2 -∆∆Ct . 18S gene is a commonly used internal standard or housekeeping gene and we and others (Koch et al., 2002) have found it to be less sensitive to variability due to cell toxicity and induction.
Testosterone 6β-hydroxylase and MDZ 1'-hydroxylase activities in cultured hepatocytes were measured, in triplicate, by incubating testosterone (250 µM) or MDZ (20 µM) with human or rhesus hepatocytes in 10 mM HEPES buffer, at 37°C, 95% humidity, and 5 % CO 2 , for 15-30 min and 15-20 min, respectively. Kinetic studies with testosterone or MDZ were also conducted under similar conditions, but with various substrate concentrations. Samples from each well were transferred to a 96-well plate containing an equal volume of acetonitrile, and stored at 4°C until analysis by high pressure liquid chromatography for testosterone (Prueksaritanont et al., 2005) or liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) for MDZ (see below).
In Vitro Inhibition Studies. All incubations were performed in triplicate. MDZ hydroxylation was assayed in 0.2 ml of an incubation mixture, containing 10 pmol recombinant CYP3A4 or CYP3A64, 20 mM MgCl 2 , 1 mM NADPH, and 0.1 M phosphate buffer, pH 7.4.
Four µl aliquots of 50% aqueous acetonitrile (control) or various concentrations of compound A in 50% aqueous acetonitrile were co-incubated with MDZ. MDZ was prepared in 50% aqueous acetonitrile solutions from which 4 µl aliquots were taken to generate final concentrations of 5 µM; a value close to its Km value (Carr et al., manuscript in review) . In a separate experiment, a time-dependent inhibitory effect of compound A on CYP3A activity was examined using 75 pmol recombinant CYP3A64 or CYP3A4 preincubated with 5 µM compound A, 1 mM NADPH, This article has not been copyedited and formatted. The final version may differ from this version. diluted 10-fold with buffer containing 1 mM NADPH before the addition of 20 µM MDZ to start the reaction. To determine enzyme inactivation kinetics, similar procedures as described above were followed, but with 50 pmol CYP3A64 or CYP3A4, and various concentrations of compound A, at preincubation time of 5 min. For all experiments, incubations were conducted at 37°C and were terminated after 5 min by the addition of acetonitrile (0.2 ml per 0.2 ml incubation). The acetonitrile extracts were analyzed by an LC-MS/MS method (see below).
In Vivo
Studies. All studies were reviewed and approved by the Merck Research
Laboratories Institutional Animal Care and Use Committee. The in vivo studies were carried out in four rhesus monkeys (all male, body weight: 4-7 kg) in a crossover fashion, with at least a 2-3-week washout period. The same four animals were used in all studies described below. In the first two periods, the animals were pretreated with either vehicle (PEG400) or rifampin (18 and 1.8 mg/kg p.o., in PEG400, total volume given 5 ml), once daily for 5 days. The animals were fasted overnight before MDZ administration on day 5. On the morning of day 5, MDZ was administered intraportally (i.pv.) to a cannulated hepatic portal vein at 0.5 mg/kg/hr (using 1 ml/kg/hr) for 4 hr to monkeys and blood samples were collected via a saphenous or femoral vein at predose, 60, 120, 150, 180, 200, 220, 240 (end of i.pv. infusion), 270, 300, 360 , and 420 min after MDZ administration. Plasma samples were separated immediately at 10°C and kept frozen at -20°C. Urine samples also were collected for up to 48 hr post MDZ administration. In subsequent periods, studies were conducted by i.v. administration of MDZ (0.5 mg/kg/hr for 4 hr) via a cephalic vein on day 5 in animals pretreated with the vehicle PEG400 and rifampin (18 mg/kg p.o. in PEG400) for 5 days.
Subsequently, similar studies using a lower i.pv. dose of MDZ were conducted in control monkeys and those treated with compound A, instead of rifampin. In these studies, the same This article has not been copyedited and formatted. The final version may differ from this version. The kinetic parameters (K inact and K I ) of CYP3A4/CYP3A64 inactivation were determined using standard procedures as described previously (Prueksaritanont et al., 1998; Chiba et al., 1995) .
The area under the plasma concentration-time profile (AUC 0-last ) was calculated from time zero to the last detectable sampling time using the linear trapezoidal rule. The apparent terminal half-life (t 1/2 ) was estimated by dividing 0.693 by the elimination rate constant determined using least-squares regression analysis of the log-linear portion of the MDZ plasma concentration-time 
Results
In Vitro Induction of CYP3A64 and CYP3A4 by Rifampin. Cultured hepatocytes, currently the accepted and recommended method for studying CYP induction (LeCluyse, 2001; Bjornsson et al., 2003) were used in this study. Under the present experimental conditions, rifampin, at 10 µM, induced markedly (~5-10-fold) the mRNA level of CYP3A64, and modestly (~1.5 -2 fold) MDZ 1'-hydroxylase activity, in all six monkey hepatocyte preparations (Fig. 1A ).
The relatively low fold induction at the functional activity level is consistent with a previous observation in this species (Wen et al., 2002) . Under similar conditions, rifampin, at 10 µM, also appreciably increased CYP3A4 mRNA expression (~6-14-fold, Fig. 1B ) and activity (~3-10-fold),
as measured by testosterone 6β-hydroxylation ( Fig. 1B ) in all six human hepatocyte preparations.
In some subjects, the MDZ 1'-hydroxylase activity also was measured and similar results to those of testosterone 6β-hydroxylase were obtained (not shown). These results were consistent with those reported earlier with rifampin in cultured human hepatocytes (LeCluyse, 2001; Luo et al., 2003) .
Further studies on effects of various concentrations of rifampin revealed that rifampin was a potent inducer of CYP3A64. In hepatocyte preparations from two individual monkeys, the mean (range) EC 50 for CYP3A64 mRNA, and MDZ 1'-hydroxylase activity were about 0.5 (0.4 -0.6) and 0.2 (0.2 -0.2) µM, respectively. The corresponding mean (range) E max values were 6-(6 -6) and 2.2-(1.8 -2.7) fold, respectively, over control values ( Fig. 2A) . Similar results also were obtained with the testosterone 6β-hydroxylase activity ( Fig. 2A) . Additional detailed studies on kinetics of MDZ metabolism in monkey hepatocytes suggested that 10 µM rifampin treatment had little effect on the apparent K m , but increased (~2-fold) the V max for both 1'-and 4-OH MDZ ( (Fig. 1A) .
In Vitro Inhibition of CYP3A64 and CYP3A4 by Compound A. In incubations with recombinant CYP3A64 and CYP3A4, compound A suppressed the formation of 1'-OH MDZ in a concentration dependent fashion, with comparable potency; the IC 50 values (~1 µM) determined using 5µM MDZ substrate concentration were essentially identical between the 2 systems (data not shown). The inhibitory effect of compound A on CYP3A64-mediated MDZ 1'-hydroxylase activity was also time-dependent, similar to that obtained with CYP3A4 (Figs. 3A and B) and consistent with the earlier finding in human liver microsomes (Chiba et al., 1995) . Enzyme kinetics studies suggested that compound A was a potent and efficient mechanism-based inhibitor of both CYP3A64 and CYP3A4, as measured by MDZ 1'-hydroxylase activity, relative to known mechanism-based inhibitors (Ernest et al., 2005) ; values for K I were 0.25 and 0.4 µM and k inact were 0.4 and 0.7 min -1 , for CYP3A64 and CYP3A4, respectively. Interestingly, comparable results also were obtained in our preliminary study with monkey and human liver microsomes;
values for K I were 0.15 and 0.26 µM, and k inact were 0.4 and 0.7 min -1 , respectively (data not DMD#9878 from 24 to 32 ml/min/kg, with a mean value of 27 ml/min/kg (Table 1 ). The major metabolite 1'-OH MDZ was detectable in plasma plasma, although with relatively low levels, in all four monkeys (Fig. 4B) . The AUC in all four monkeys (Fig. 4B) ; the AUC values of 1'-OH MDZ ranged from 0.2 to 0.9 µM⋅hr, representing about 13% (range: 5 to 22%) of those for the parent MDZ (Table 1) . Plasma levels of 4-OH MDZ were near detectable limit and thus not shown, in control monkeys. Analysis of urine samples revealed that the total urinary recovery of MDZ and its metabolites were about 67% of the i.v. dose, with 1'-OH MDZ glucuronide representing the major metabolite (65% of the dose) and 4-OH MDZ being the minor pathway (<1% of the dose) ( Table 1 ). Noteworthy that complete assessment of the in vivo MDZ metabolism in rhesus monkeys was not possible since recoveries of MDZ and its metabolites in feces via biliary excretion were not determined in this study. Nevertheless, the urinary analysis suggested that in rhesus monkeys, MDZ underwent extensive metabolism via oxidation (at least 67%) followed by glucuronidation, and that urinary excretion was the major (~70%) elimination pathway.
Treatment with rifampin for 5 days at 18 mg/kg p.o. did not significantly affect the i.v.
plasma profiles (Fig. 4A ) or pharmacokinetic parameters of MDZ; values for AUC, V dss , CL and t 1/2 of MDZ were comparable between the control and rifampin treated animals (Table 1) .
However, rifampin significantly decreased plasma levels of 1'-OH MDZ (Fig. 4B) ; values for 1'-OH MDZ were decreased to approximately 1% of that of MDZ, representing about 10% of the control value (Table 1) . A metabolite switching phenomenon was not apparent as a similar decreasing trend in plasma levels of 4-OH MDZ also was observed in rifampin treated vs control animals (data not shown). In control animals, MDZ plasma levels obtained after i.pv. administration were significantly lower than those observed following i.v. administration, with an apparent steady-state concentration of about 0.3 µM (range 0.1 to 0.4 µM) and AUC of 0.7 µM⋅hr (Fig. 5A , Table 2 ).
Effects of Rifampin on the Pharmacokinetics of MDZ after Intraportal Vein
As a consequence, the hepatic availability, F h , of MDZ was low (16%, Table 2 ), suggesting extensive hepatic first pass elimination of MDZ in control monkeys. Consistent with this, ratios between plasma levels of 1'-OH MDZ and MDZ following i.pv. administration of MDZ (Fig. 5B) were higher than those obtained following the i.v. dosing; a mean value for 1'-OH/MDZ AUC ratio was about 2 (Table 2) .
Unlike the observation with the i.v. administration, treatment of rifampin at 18 mg/kg p.o.
for 5 days caused a pronounced decrease (~90%) in MDZ AUC after i.pv. administration of MDZ (Table 2) . Consequently, the F h , of MDZ was markedly decreased to 1% by rifampin treatment. A similar magnitude of interactions also was obtained following administration of rifampin at 1.8 mg/kg p.o. for 5 days ( Fig. 5A ; Table 2 ), suggesting that an apparent maximal induction effect of rifampin was reached at the doses employed in this study. As was the case with the i.v. dosing, marked decreases in 1'-OH MDZ AUC also were observed in monkeys treated with rifampin, either at 18 or 1.8 mg/kg (Fig. 5B , Table 2 ). However, the AUC ratios between 1'-OH MDZ and MDZ in these animals, at both doses, although slightly higher than (~20-43%), were not statistically significant from control values ( Table 2) .
In monkeys pretreated with rifampin, plasma concentrations of rifampin were maintained above 5 and 0.2 µM, following 18 and 1.8 mg/kg doses, respectively, over a period of 6 hr after the last dose (5 th dosing day) (Fig. 6 ). As shown in Table 2 , systemic exposures of rifampin were increased as doses increased, although more than dose proportional; plasma levels of rifampin reached C max of about 15 µM and 0.3 µM, and values for AUC 0-7hr of rifampin were 67 and 1.2 µM⋅hr, after 18 and 1.8 mg/kg, respectively ( animals, plasma levels of MDZ were relatively low (Fig. 7) , with mean AUC value of 0.03 µM⋅hr (Table 3) . Consistent with the finding with the 0.5 mg/kg/hr MDZ dose, 1'-OH MDZ plasma levels were substantial; the AUC ratio between 1'-OH MDZ and MDZ was about 1.6 (Fig. 7 , Table 3 ).
Treatment with compound A caused marked increases in the AUC values of both MDZ and 1'-OH MDZ by 10-fold and 4-fold, respectively (Fig. 7, Table 3 ), resulting in statistically significant decreases in the 1'-OH MDZ/MDZ AUC ratio to about 60% (Table 3) . Also, a similar increasing trend in plasma levels of 4-OH MDZ were observed in animals treated with compound A (data not shown). At the dose of compound A used in this study, plasma levels of compound A were above 0.5 µM for about 6 hr ( Fig. 5) , with a mean AUC 0-8hr value of 7 µM⋅hr (Table 3) .
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
In the present in vitro studies, rifampin was characterized as an equipotent inducer of both rhesus monkey CYP3A64 and human CYP3A4, while compound A was equally efficient as an inactivator of CYP3A64 and CYP3A4. Subsequent pharmacokinetic interaction studies with MDZ, showed that in vivo, rhesus monkey CYP3A64 also was susceptible to induction by rifampin and inhibition by compound A. As is the case for CYP3A4 in humans, the in vivo clearance mechanism of MDZ in rhesus monkeys likely is primarily via CYP3A64, qualifying MDZ pharmacokinetics as an in vivo CYP3A64 probe. This conclusion is supported by 1) the finding that MDZ underwent extensive metabolism (at least 67%) in rhesus monkeys, with 1'-OH MDZ constituting the major metabolic pathway (Table 1) Pharmacokinetically, MDZ was characterized as a high clearance compound in rhesus monkeys, based on a blood/plasma partition ratio for MDZ of 0.6 (data not shown) and a mean CL of 27 ml/min/kg (Table 1) , yielding a mean blood clearance (about 45 ml/min/kg) approaching the hepatic blood flow reported for this species (50-55 ml/min/kg). Interestingly, this in vivo clearance observation also is consistent with the high basal MDZ 1'-hydroxylase activity observed in vitro with CYP3A64.
This article has not been copyedited and formatted. The final version may differ from this version. In this study, the pharmacokinetics of 1'-OH MDZ also was monitored, but unfortunately limited information was attained. Unlike the in vitro metabolite formation kinetics, in vivo metabolite kinetics is known to be quite complex, dependent not only on its formation rate, but also its elimination rate as well as the exposure of its parent (Houston, 1982) . The finding that the exposure to 1'-OH MDZ was markedly decreased with a comparable decrease in 1'-OH MDZ/MDZ AUC ratios after i.v. administration of MDZ to monkeys pretreated with rifampin suggested that rifampin might also induce a major elimination process of 1'-OH MDZ, presumably glucuronidation. This suggestion is in agreement with published reports that rifampin is an inducer for UGT (Li et al., 1999; Soars et al., 2004) . However, the reasons for the different Analogous to rhesus monkeys, an apparent in vitro-in vivo agreement also was obtained with MDZ and rifampin in humans. In clinical studies, rifampin has been reported to significantly increase the i.v. CL (2-fold) and decrease oral exposure of MDZ (20-40-fold) (Backman et al., 1996 (Backman et al., , 1998 Kharasch et al., 2004) . The effect on CL is consistent with the in vitro induction data observed in human hepatocytes, as well as the fact that MDZ exhibits a moderate CL in humans (unlike monkeys), while that on the oral AUC could be attributable additionally to changes in the hepatic first pass as well as the induction of CYP3A4-mediated intestinal first pass of MDZ (Thummel et al., 1994; Tsunoda et al., 1999) . In this regard, the i.pv. administration was used in the present monkey study to avoid potential complications from incomplete absorption and intestinal enzyme induction or inhibition. This allowed for a direct comparison with the present in vitro studies using liver preparations. Although not studied, the inhibitory effect of compound A on the MDZ pharmacokinetics in humans is also expected to be comparable to that observed in the present rhesus monkey study, based on almost identical in vitro CYP3A64 and CYP3A4 data, human CYP3A4. In the case of rifampin, the enzyme inducing effect in rhesus monkeys appeared to be mediated via the pregnane X receptor, PXR, (Merck Research Labs, data on file), similar to humans (Gibson et al., 2002; Luo et al., 2002) . Nevertheless, species differences in CYP responses between rhesus monkeys and humans remain a possibility for other compounds, considering the well documented marked species differences, especially between rodents and humans in response to CYP3A inducers (Gibson et al., 2002) .
In conclusion, the present investigation showed that in vitro, rhesus monkey CYP3A64 Values are Mean ± SD, n=4.
Values in parentheses are range.
*Indicates statistically significant difference from control (p < 0.05).
